Clinical Trial Update: MRI With Gadoxetate Disodium in Measuring Tumors in Patients With Liver Cancer [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating MRI with the contrast agent gadoxetate disodium to measure tumor burden in adults with hepatocellular carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Gadoxetate disodium (gadoxetate disodium)

Snippet

Sponsor: University of Southern California | Conditions: Adult Hepatocellular Carcinoma, Advanced Adult Hepatocellular Carcinoma | Phase 1 | Status: COMPLETED